Cardiff Oncology (CRDF) Current Assets (2011 - 2026)

Cardiff Oncology has reported Current Assets for 15 years, with the latest figure at $60.1 million in Q4 2025.

• Quarterly Current Assets fell 36.74% year-over-year to $60.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $60.1 million (down 36.74% YoY) and the FY2025 annual result came in at $60.1 million, down 36.74% from the prior year.
• Current Assets slipped to $60.1 million in Q4 2025 per CRDF's latest filing, from $61.8 million in the prior quarter.
• Over five years, Current Assets peaked at $146.1 million in Q4 2021 and troughed at $59.3 million in Q3 2024.
• A 5-year average of $98.5 million and a median of $93.9 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2021 and 2025: Current Assets jumped 1150.33% in 2021, then tumbled 36.74% in 2025.
• Over 5 years, Current Assets stood at $146.1 million in 2021, then dropped by 23.84% to $111.3 million in 2022, then sank by 30.44% to $77.4 million in 2023, then grew by 22.79% to $95.1 million in 2024, then sank by 36.74% to $60.1 million in 2025.
• According to Business Quant data, Current Assets over the past three periods registered $60.1 million, $61.8 million, and $73.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.